PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance
August 24, 2022 16:01 ET
|
PDS Biotechnology Corporation
Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT FLORHAM PARK,...
PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update
August 08, 2022 07:00 ET
|
PDS Biotechnology Corporation
Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology...
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications
August 04, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotech to Participate at BTIG Biotechnology Conference 2022
August 02, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer...
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results
July 26, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virology Meeting
July 14, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., July 14, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel
June 03, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted...
PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101
June 02, 2022 08:00 ET
|
PDS Biotechnology Corporation
PDS Biotech has been granted Fast Track designation for PDS0101 in combination with KEYTRUDA® (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer FLORHAM...
PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe
May 31, 2022 08:00 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer...